Core Biogenesis

Founded in 2020, Core Biogenesis is a France-based biotechnology firm focussing on recombinant protein development. It uses a ultra-scalable bioproduction as a service (UBaaS) platform to derive plant-based protein by using camelina sativa oilseed plant. According to the company, by inserting DNA into the plant, they are able to use photosynthesis to achieve the proteins required without the use of bioreactors or vertical farming technologies, thus making the entire process carbon-negative. Further, the company claims its combination of patent pending technology and animal-free growth factors enable a more cost-effective and commercially viable process for cell therapy manufacturing, which can be used for a range of applications including therapeutics and cultivated meat production.

Core Biogenesis developed FGF-2 STAB, a novel, thermostabilized form of FGF-2. This engineered growth factor was designed to support FGF-2-dependent cell cultures more efficiently, requiring fewer media changes due to its increased half-life and heat tolerance while maintaining full bioactivity.

Funding and financials

In July 2022, the company raised USD 10.5 million in a Series A funding round led by XAnge with participation from Blue Horizon Ventures and Thia Ventures. The funds were intended for building an industrial-scale facility and additional staff hires for expansion.